Holen Sie sich die Stockscreener-App
98.51
0.78%
0.76
Schlusskurs vom Vortag:
$97.75
Offen:
$98.92
24-Stunden-Volumen:
362.59K
Relative Volume:
0.52
Marktkapitalisierung:
$4.12B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-104.80
EPS:
-0.94
Netto-Cashflow:
-
1W Leistung:
+0.59%
1M Leistung:
-8.17%
6M Leistung:
+108.05%
1J Leistung:
+0.00%
1-Tages-Spanne:
$97.20
$99.89
1-Wochen-Bereich:
$95.42
$101.38
52-Wochen-Spanne:
$32.00
$131.24
Veradermics Inc Stock (MANE) Company Profile
Firmenname
Veradermics Inc
Sektor
Branche
Telefon
228.372.3376
Adresse
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
98.51 | 4.40B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | Citigroup | Buy |
| 2026-03-02 | Eingeleitet | Jefferies | Buy |
| 2026-03-02 | Eingeleitet | Leerink Partners | Outperform |
Veradermics Inc Aktie (MANE) Neueste Nachrichten
Veradermics (NYSE:MANE) Director Sells 750,000 Shares - MarketBeat
Veradermics (MANE) backer exercises $0.00001 per share warrants - Stock Titan
Veradermics (NASDAQ: MANE) insider sells stock in two August trades - Stock Titan
Veradermics (MANE) R&D chief enters insider ranks with no stake - Stock Titan
Veradermics (NYSE:MANE) Stock Price Down 7.9%Here's Why - MarketBeat
Form 144 | Veradermics(MANE.US) Insider Proposes to Sell 6.37 Million in Common Stocks - Moomoo
Veradermics (MANE) affiliate plans NYSE sale via BofA Securities - Stock Titan
Veradermics CEO Reid Alexander Waldman disposes of common shares worth $7.24 million - Bitget
Veradermics (NYSE:MANE) Insider Timothy August Durso Sells 43,500 Shares - MarketBeat
Veradermics (NYSE:MANE) CEO Reid Alexander Waldman Sells 67,500 Shares of Stock - MarketBeat
Veradermics(MANE.US) Officer Sells US$4.69 Million in Common Stock - Moomoo
Veradermics (MANE) CTO unloads tens of thousands of shares in preset trades - Stock Titan
Veradermics (MANE) CEO sells shares under preset trading plan - Stock Titan
Veradermics (MANE) Institutional Ownership 2026 - MarketBeat
Veradermics (MANE) affiliate lines up NYSE share sale - Stock Titan
Veradermics (NYSE: MANE) holder lines up $15M stock sale - Stock Titan
Veradermics, Inc SEC Filing (Aug 17, 2026) - Stock Titan
Veradermics (MANE) holder SR One sells 321,749 shares, cuts stake to 4.9% - Stock Titan
John Childs Sells 100,000 Shares of Veradermics (NYSE:MANE) Stock - marketbeat.com
Planned MANE (MANE) insider common stock sale and recent IPO activity - Stock Titan
Veradermics (MANE) director-linked trusts sell 100,000 shares of common stock - Stock Titan
Veradermics (MANE) Stock Forecast and Price Target 2026 - MarketBeat
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $160 - Moomoo
Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164 - Moomoo
Veradermics, Inc SEC Filing (Aug 12, 2026) - Stock Titan
Veradermics: Q2 Earnings Snapshot - theheraldreview.com
MANE SWOT Analysis: Financial Challenges and Competitive Landsca - GuruFocus
Veradermics Q2 Results: EPS of $(0.58) Beats Estimate - scanx.trade
Veradermics (NYSE: MANE) posts larger loss as cash surges above $800M - Stock Titan
Veradermics Announces Q2 2026 Financial Results in SEC 8-K Filing - Kalkine Media
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Form 8K VERADERMICS For: 11 August By Investing.com - Investing.com Australia
Veradermics reports Q2 2026 net loss $23.5M; cash $819.9M funds operations into 2030 - TradingView
Veradermics' Q2 Net Loss Widens - marketscreener.com
Earnings Flash (MANE) Veradermics Posts Q2 Net Loss $23.5M, vs. FactSet Est of $26.8M Loss - marketscreener.com
IPO Databook: Veradermics (MANE US)Aug 2026 - Smartkarma
FMR LLC discloses 7.6% Veradermics Inc. (MANE) ownership in Schedule 13G - Stock Titan
Enterprise value to EBIT forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Price to earnings forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Price to sales forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Enterprise value to revenue forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Veradermics (MANE) Positioned to Disrupt Hair Loss Market - Yahoo Finance
Veradermics, Inc. (MANE): Six Months Later: Hair Today, Higher Tomorrow, 2026's Breakout Story - Smartkarma
Veradermics Falls 4.4% as Lock-Up Expiry Appears to Weigh on Shares - Moomoo
Certain Options of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 3-AUG-2026. - marketscreener.com
14,570,076 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026. - marketscreener.com
Veradermics, Incorporated's Lock-Up Period Set To End on August 3rd (NYSE:MANE) - marketbeat.com
Veradermics, Incorporated Revenue Breakdown – NYSE:MANE - TradingView
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Yahoo Finance
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $170 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Veradermics Inc-Aktie (MANE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):